未登录Chemokine12 (CK12) tertiary lymphoid gene expression signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY 2 TRIAL - pembrolizumab with and without SD101, and durvalumab combined with olaparib - and in 9 other arms of the trial including platinum-based and dual-anti-HER2 therapies
Soliman, Hatem; Wolf, Denise; Chien, Jo; Yau, Christina; Campbell, Michael; Magbanua, Mark; Lu, Ruixiao; O'Grady, Nicholas; Brown-Swigart, Lamorna; Hirst, Gillian; Parker, Beverly; Sit, Laura; Asare, Smita; Yee, Doug; DeMichele, Angie; Nanda, Rita; Pusztai, Lajos; Berry, Don; Esserman, Laura; Van't Veer, Laura
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏Pursuing Molecular Stratification in Phase I Trials
Kurzrock, R.; Tsimberidou, A. M.; Hong, D. S.; Wheler, J. J.; Falchook, G. S.; Fu, S.; Naing, A.; Janku, E.; Wen, S.; Berry, D.
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏